How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cell & Advanced Therapies Supply Chain Management Market
- By Therapy Type: Autologous Cell Therapy, Allogeneic Cell Therapy, Gene Therapy, Tissue Engineering, Regenerative Medicine
- By Supply Chain Service: Cold Chain Logistics, Cryopreservation Services, Inventory Management, Transportation and Distribution, Quality Control and Compliance
- By End User: Biopharmaceutical Companies, Contract Development and Manufacturing Organizations (CDMOs), Hospitals and Clinics, Research Institutes, Specialized Cell Therapy Centers
- By Product Type: Cell Collection Kits, Cryogenic Storage Containers, Temperature Monitoring Devices, Packaging Solutions, Transportation Containers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Autologous Cell Therapy leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Cell & Advanced Therapies Supply Chain Management Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Therapy Type 5
Supply Chain Service 5
End User 5
Product Type 5
Companies profiled
Thermo Fisher Scientific
Sartorius AG
Lonza Group AG
Catalent Inc.
Cytiva (a Danaher company)
GE Healthcare Life Sciences
Fresenius Kabi
Cryoport Inc.
BioLife Solutions Inc.
Parata Systems
LLC
BioCision
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Lonza Group AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Catalent Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Cytiva (a Danaher company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →GE Healthcare Life Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Fresenius Kabi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Cryoport Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →BioLife Solutions Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Parata Systems
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →LLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →BioCision
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Asymptote
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Helios
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →BioStorage Technologies
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Cytothera
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,056M by 2033 · 7.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Autologous Cell Therapy50.2
- Allogeneic Cell Therapy17.5
- Gene Therapy13.9
- Tissue Engineering7.1
- Regenerative Medicine11.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$386.4M → $670.0M · 7.1%
Europe$269.3M → $447.8M · 6.6%
Asia Pacific$245.9M → $442.8M · 7.6%
Latin America$152.2M → $248.9M · 6.3%
Middle East and Africa$117.1M → $213.5M · 7.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.242026
7.252027
7.282028
7.272029
7.292030
7.312031
7.322032
7.342033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific10.7
- Sartorius AG25.5
- Lonza Group AG5.4
- Catalent Inc.8.3
- Cytiva (a Danaher company)11.6
- GE Healthcare Life Sciences10.4
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapy Type11.3%
Supply Chain Service20.1%
End User32.1%
Product Type36.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.1
- Europe22.1
- Asia Pacific21.9
- Latin America12.3
- Middle East and Africa10.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 73 | 80 | 83 | 90 | 81 | 85 | 82 |
| Sartorius AG | 87 | 71 | 80 | 81 | 83 | 82 | 81 |
| Lonza Group AG | 66 | 67 | 72 | 72 | 82 | 83 | 74 |
| Catalent Inc. | 78 | 78 | 80 | 59 | 58 | 78 | 72 |
| Cytiva (a Danaher company) | 74 | 77 | 58 | 53 | 61 | 65 | 65 |
| GE Healthcare Life Sciences | 71 | 71 | 66 | 51 | 56 | 62 | 63 |
| Fresenius Kabi | 52 | 58 | 41 | 45 | 55 | 57 | 51 |
| Cryoport Inc. | 55 | 54 | 59 | 50 | 35 | 59 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Sartorius AG
- Lonza Group AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Sartorius AG | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Lonza Group AG | − | − | ◐ | ◐ | ◐ | ✓ |
| Catalent Inc. | ◐ | ✓ | ✓ | ◐ | − | ◐ |
| Cytiva (a Danaher company) | ✓ | ◐ | − | ◐ | ◐ | ◐ |
| GE Healthcare Life Sciences | ✓ | ◐ | ✓ | ◐ | − | − |
| Fresenius Kabi | − | ◐ | − | − | ◐ | ◐ |
| Cryoport Inc. | ◐ | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific82
2Sartorius AG81
3Lonza Group AG74
4Catalent Inc.72
5Cytiva (a Danaher company)65
6GE Healthcare Life Sciences63
7Cryoport Inc.52
8Fresenius Kabi51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificSartorius AG
Challenger2
Strong scale, closing on the leaders.
Lonza Group AGCatalent Inc.
Contender2
Focused players with pockets of strength.
Cytiva (a Danaher company)GE Healthcare Life Sciences
Niche2
Specialists in a single segment or region.
Fresenius KabiCryoport Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapy Type in North America, then scale across Cell & Advanced Therapies Supply Chain Management Market — a $337M beachhead inside a $4.67B market.
Beachhead (SOM)$337Mobtainable near-term
Serviceable (SAM)$1.88Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Autologous Cell Therapy
Best fit — highest urgency & budget in Therapy Type.
Economic buyer78 fit
Allogeneic Cell Therapy
Strong fit — clear ROI and a fast path to value.
End user65 fit
Gene Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Supply Chain Service & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cell & Advanced Therapies Supply Chain Management Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified22%
Evaluation12%
Closed-won6%
$8.0KCAC
$35KLTV
4.3:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cell & Advanced Therapies Supply Chain Management Market is a durable-growth opportunity — $3.73B by 2033, compounding at 9.3%.
TAM · 2025$1.83Btoday
TAM · 2033$3.73Bforecast
CAGR9.3%2027–2033
Cumulative$24.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.73BTotal addressable market
SAM$1.45BServiceable available market
SOM$295MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.3% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.73BLarge & growingTAM by 2033 at 9.3% CAGR
$1.45BServiceable nowreachable with today’s model
$295MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.91BBear6.0% CAGR
$3.73BBase9.3% CAGR
$4.78BBull12.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Supply Chain Service optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cell & Advanced Therapies Supply Chain Management Market — a $2.88B market by 2033. Plan: grow share from 8.9% to 14.0%.
Market size · 2033$2.88Btotal addressable
Market CAGR9.4%2027–2033
Target share14.0%from 8.9% today
Revenue ambition$403Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.9% | 14.0% | On track |
| Revenue | $234M | $403M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 32.7% | 41.7% | At risk |
| Customer retention | 84.5% | 92.2% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Supply Chain Service capability
A defensible second engine — invest in Supply Chain Service to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Supply Chain Service
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $55M capacity & capability investment
- Greenlight bolt-on M&A in Supply Chain Service
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cell & Advanced Therapies Supply Chain Management Market conversation — a $5.20B market you can size, segment and defend in minutes.
Market size · 2033$5.20Btotal opportunity
Growth8.6%CAGR to 2033
Addressable buyers1,632+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 2 mopayback period
$76K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Thermo Fisher ScientificSartorius AGLonza Group AGCatalent Inc.Cytiva (a Danaher company)GE Healthcare Life SciencesFresenius KabiCryoport Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cell & Advanced Therapies Supply Chain Management Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cell & Advanced Therapies Supply Chain Management Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cell & Gene Delivery Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportCell & Gene Therapy Cold Chain Logistics Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportCell & Gene Therapy Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportCell Activation Devicer Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportCell Analyzer Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCell and Gene Therapy (CGT) Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportCell and Gene Therapy CDMO Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportCell and Gene Therapy CDMO Services Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportCell and Gene Therapy Related Products Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportCell Anemia Testing & Screening Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportCell Assay Reagents Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportCell Based Collagen and Gelatin Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.